| Document |
Document Title |
|
WO/2020/168152A2 |
Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selec...
|
|
WO/2020/163240A1 |
Described herein is the use of PPARδ agonists in the treatment of fatty acid oxidation disorders.
|
|
WO/2020/157201A1 |
The present invention includes name compounds of general formula (I) in which R1, Y, and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositio...
|
|
WO/2020/151687A1 |
Provided is an N-benzyl-N-arylsulfonamide derivative, which is an N-benzyl-N-arylsulfonamide compound represented by a general formula (I), or a pharmaceutically acceptable salt or solvate thereof. The N-benzyl-N-arylsulfonamide derivati...
|
|
WO/2020/152037A1 |
A radiation curable inkjet ink containing at least one or two compounds selected from the group consisting of a polymerizable compound including a vinylether group or a vinylamide group, an amine synergist including an alkanolamine group...
|
|
WO/2020/152010A1 |
The present application relates to a novel, cost-saving and efficient process for preparing 4-(2,2,3,3-tetrafluoropropyl)morpholine which serves as an intermediate for production of medicaments and for production of medicaments for treat...
|
|
WO/2020/142503A1 |
In alternative embodiments, the provided are therapeutic combinations comprising: nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibi...
|
|
WO/2020/141419A2 |
The present invention relates to novel pharmaceutically acceptable salts of Bempedoic acid, novel intermediates of Bempedoic acid, novel crystalline form of Bempedoic acid and novel processes for the preparation of Bempedoic acid or its ...
|
|
WO/2020/138398A1 |
The present invention addresses the problem of providing a novel compound exhibiting a high LSD1-inhibiting activity, high selectivity for LSD1 inhibition, and/or having a useful therapeutic effect for various diseases. One embodiment pe...
|
|
WO/2020/124351A1 |
An application of a glutamine derivative in preparation of an animal feed additive, specifically, the application of a glutamine derivative the structure of which is shown in the followng formula (I) or racemates, stereoisomers, geometri...
|
|
WO/2020/122341A1 |
The present invention relates to a novel cinnamic acid derivative having an excellent antibacterial effect and an antibacterial composition comprising same. Specifically, the present invention relates to an antibacterial composition comp...
|
|
WO/2020/123670A1 |
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperazine (or similar) structure which function as antagonists of androgen receptor activity, and the...
|
|
WO/2020/118118A1 |
The present disclosure relates to fluoride ion batteries and structures of metal based electrode materials for various fluoride ion batteries. The structures of the metal based electrode materials comprise one or more shells or interface...
|
|
WO/2020/114150A1 |
A synthesis method for a carbamate using dimethyl sulfoxide ylide, amine and carbon dioxide is provided. The carbamate is obtained by adding dimethyl sulfoxide ylide, an amine and a solvent into a pressure reactor, then adding a catalyst...
|
|
WO/2020/118041A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/114853A1 |
The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)- 1,2,2-trimethylpiperazine in the form of 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro- 1H-inden-1-yl)-2,2-dimethyl-1-(m...
|
|
WO/2020/111921A1 |
The present invention relates to a new class of small anti-cancer molecules derived from ethacrynic acid (symbolized by AE). The invention relates to the in vitro and in vivo anti-cancer activities and to the methods for producing the ne...
|
|
WO/2020/109148A1 |
A photoinitiator selected from the group consisting of an acylphosphine oxide, a α-hydroxy-ketone and a α-amino-ketone, characterized in that the photoinitiator includes at least one aliphatic disulfide as functional group.
|
|
WO/2020/104822A1 |
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is...
|
|
WO/2020/102901A1 |
Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium...
|
|
WO/2020/098710A1 |
Provided in the present application are a substituted bis-aryl amide compound and a preparation method and an application therefor, the substituted bis-aryl amide compound or a pharmaceutically acceptable salt thereof having the structur...
|
|
WO/2020/092082A1 |
Embodiments relate to a continuous process for the production of hydroxyethylpiperazine that includes feeding neat piperazine, recycled piperazine, and ethylene oxide to a reactor to form crude hydroxyethylpiperazine, in which the reacto...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085373A1 |
The present invention provides a novel compound which has activating activity selective for ERβ. A compound represented by formula (1) or a salt thereof. (In the formula, R1 represents a cycloalkyl group having 3-8 carbon atoms, an alke...
|
|
WO/2020/072324A1 |
The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for ...
|
|
WO/2020/072456A1 |
Disclosed is a pharmaceutical composition comprising a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of tre...
|
|
WO/2020/067398A1 |
The purpose of the present invention is to provide: a novel compound that inhibits cell invasion of filovirus; a medicinal composition that comprises the compound; an anti-filovirus agent or an inhibitor for cell invasion of filovirus; a...
|
|
WO/2020/061293A1 |
The present disclosure relates to compounds useful as shielding agents for PSMA therapies. The present disclosure relates to methods of treating PSMA expressing cancers with one or more radiotherapeutics agents in combination with one or...
|
|
WO/2020/059841A1 |
The purpose of the invention is to provide a compound which has the effect of suppressing abnormal prion production and is useful as a therapeutic agent for prion diseases. Provided are a compound represented by formula (I) (the symbols ...
|
|
WO/2020/054226A1 |
A thermal base generator is represented by formula (N1). This photosensitive resin composition contains the thermal base generator and a precursor of a heterocycle-containing polymer. In formula (N1), RN1 and RN2 each independently repre...
|
|
WO/2020/050160A1 |
A hydrogenation catalyst for amide compounds which comprises hydroxyapatite and, fixed thereto, platinum and vanadium, characterized in that 15-80% of the surface of the platinum is covered with vanadium. With the catalyst, it is possibl...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/046515A1 |
The present disclosure provides a quaternary ammonium hydroxide solution comprising a reaction product of a polyamine and an organic oxirane. The quaternary ammonium hydroxide solution may be used in various applications, such as in remo...
|
|
WO/2020/042876A1 |
The present application relates to a synthesis method for cariprazine, comprising performing an acylation reaction between a compound represented by formula (I) and dimethylcarbamoyl chloride in a reaction solvent in the presence of an a...
|
|
WO/2020/039092A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/039094A1 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/039088A2 |
The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
|
|
WO/2020/039631A1 |
Disclosed is a compound represented by formula (1): Q-CHR2 (1) (in the formula, Q represents a nitrogen-containing aliphatic group that includes two or more tertiary nitrogen atoms, and does not include oxygen, and R represents an alipha...
|
|
WO/2020/035464A1 |
The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 and R3 are each independently hydrogen or an optionally substituted hydrocarbyl group, or R1 and R3 together with the nitrogen atom to which...
|
|
WO/2020/036661A2 |
The disclosure relates to a method for forming aryl carbon-nitrogen bonds and to photoreactors useful in these and other light-driven reactions. The method comprises contacting an aryl halide with an amine in the presence of a Ni salt ca...
|
|
WO/2020/035825A1 |
The present invention disclosed novel phenylamidine compounds of formula (I), wherein, Cy, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and m have the same meanings as defined in the description.The present invention further discloses a proce...
|
|
WO/2020/035031A1 |
Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by ...
|
|
WO/2020/031986A1 |
The present invention addresses the problem of providing: a compound which exhibits high solubility in a solvent, while having a satisfactory sensitivity (base generation capacity); a polymerizable composition which contains this compoun...
|
|
WO/2020/027304A1 |
Provided are carotenoid derivatives having exceptional hydrophilicity and oral absorptivity. A carotenoid-related compound represented by the formula (in the formula, X represents a carbonyl group or a methylene group, and Z1 and Z2 are ...
|
|
WO/2020/027150A1 |
A compound represented by general formula (I) (wherein each symbol is as defined in the description) or a salt thereof has a potent neural protecting and/or repairing effect and, therefore, is usable as a therapeutic agent for neurologic...
|
|
WO/2020/023793A1 |
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
|
|
WO/2020/021021A1 |
The present invention relates to ortho substituted phenoxypropylamino and benzyloxypropylamino derivatives having pharmacological activity towards the α2δ subunit of the voltage-gated calcium channel, in particular to ortho substituted...
|
|
WO/2020/023794A1 |
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
|
|
WO/2020/013108A1 |
To provide a drug for enabling the treatment or prevention of diseases which are caused by mitochondrial dysfunction and called mitochondrial diseases. In particular, to search for a function effect on mitochondrial diseases, said functi...
|
|
WO/2020/011147A1 |
Provided herein are compounds as RORγ antagonist having Formula (I). The compounds or pharmaceutical composition thereof can be used for regulating Retinoid-related orphan receptor gamma t (RORγt). Also provided herein are methods of p...
|
